NCT00761384View on ClinicalTrials.gov

High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

B-cell Lymphoma

Interventions

DRUG

90Y-ibritumomab

90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.

Trial Locations (1)

221 85

Lund University Hospital, Lund